2008年新版英国MRSA感染预防和治疗指南

David

JAC Advance Access published online on March 12, 2009
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkp065

ReviewGuidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom2008年新版英国MRSA感染预防和治疗指南
F. Kate Gould1,*, Richard Brindle2, Paul R. Chadwick3, Adam P. Fraise4, Simon Hill5, Dilip Nathwani6, Geoff L. Ridgway7, Michael J. Spry1, Rod E. Warren8 on behalf of the MRSA Working Party of the British Society for Antimicrobial Chemotherapy
1 Department of Microbiology, Freeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne NE7 7DN, UK 2 Department of Microbiology, Queen Alexandra Hospital, Portsmouth PO6 3LY, UK 3 Department of Microbiology, Salford Royal Hospital, Salford M6 8HD, UK 4 Department of Medical Microbiology, City Hospital NHS Trust, Dudley Road, Birmingham B18 7QH, UK 5 Department of Microbiology, Poole Hospital, Longfleet Road, Poole BH15 2JB, UK 6 Infection Unit, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK 7 Department of Health, Wellington House, 133-135 Waterloo Road, London SE1 8UG, UK 8 Department of Microbiology, Royal Shrewsbury Hospital, Mytton Oak Road, Shrewsbury SY3 8XQ, UK * Corresponding author. Tel: +44-191-223-1248; Fax: +44-191-223-1224; E-mail: kate.gould@nuth.nhs.uk
These evidence-based guidelines are an updated version of those published in 2006. They have been produced after a literature review of the treatment and prophylaxis of methicillin-resistant Staphylococcus aureus (MRSA). The guidelines aim to complement those recently published for the antibiotic treatment of common and emerging community-onset MRSA infections in the UK. The guidelines have reviewed and updated, where appropriate, previous recommendations, taking into account any changes in the UK epidemiology of MRSA, ongoing national surveillance data and the value of new antistaphylococcal agents licensed for use in UK practice. Emerging therapies that have not been licensed for UK use are not reviewed, but their future potential role has been mentioned where deemed appropriate. Recommendations are given for the treatment of common infections caused by MRSA, elimination of MRSA from carriage sites and prophylaxis of surgical site infection. Key Words: update , evidence-based guidelines , meticillin , new antistaphylococcal agents , UK